Tempus AI is set to acquire Personalis, the cancer genomics testing company, in a merger valued at $16.25 per share — but the deal is not done yet, and it is already being scrutinised. The agreement was announced on July 20, 2026. Personalis shareholders are scheduled to vote on it at a special meeting on Monday, November 30, 2026, and a securities law firm has opened an investigation into whether the price is fair.
The distinction matters: this is a definitive agreement awaiting a shareholder vote, not a completed acquisition. Reporting on the deal in late October and early November 2026 describes it as pending, with the registration statement on Form S-4 declared effective on October 21 and the proxy statement mailed to holders on or about that date.
How the $16.25 Offer Works
Tempus is offering $16.25 a share in its Class A common stock, and it can elect to pay up to 50 percent of the consideration in cash. A collar sets the exchange ratio: if the Tempus stock price is above $48.42, the ratio is $16.25 divided by that price; at or below $48.42, it is fixed at 0.3356 Tempus shares per Personalis share. The Tempus stock price used for the calculation is the volume-weighted average Nasdaq price over the 15 trading days before, but not including, the last trading day before closing.
The collar is the part of the deal that most affects what Personalis shareholders actually receive. While the Tempus price stays above $48.42, the value of the consideration holds near $16.25 a share. If Tempus shares fall below that level, the fixed ratio means the value of the consideration falls with them. Personalis's board has unanimously recommended that shareholders vote in favour, pitching a 28 percent premium to the unaffected 30-day volume-weighted average price and a 64 percent premium to the unaffected 90-day average, according to a Rule 425 merger communication filed in late October.
Why the Deal Is Being Investigated
On November 9, 2026, securities law firm Bleichmar Fonti & Auld announced it is investigating the merger, on the grounds that Tempus is not an arms-length buyer. As of March 2026, Tempus owned 12.5 percent of Personalis's outstanding common stock, and since November 2023 the two companies have had an ongoing commercial relationship covering commercialisation and laboratory services. The firm is examining whether that prior relationship caused breaches of fiduciary duty and whether $16.25 is a fair price for public stockholders.
This kind of investigation is routine after announced mergers — law firms regularly announce them, and they do not by themselves indicate wrongdoing. But the underlying issue is a real one in M&A law: when the buyer already owns a significant stake and has a commercial relationship with the target, the negotiation is not between two independent parties, and minority shareholders need extra protection. That is why the proxy filing warns of the risks of the standalone alternative, including competition from established, well-funded incumbents and the dilutive financing Personalis would need to raise on its own.
What Personalis Does
Personalis provides cancer genomic testing, including its NeXT Personal platform for detecting minimal residual disease — the tiny traces of cancer that remain after treatment and can signal a relapse. The company reported third-quarter 2026 results in early November: sales rose 77 percent to $25.6 million, while losses also grew, and cash and short-term investments stood at $190.6 million on September 30, 2026, down from $240.0 million at the end of 2025. A U.S. Department of Veterans Affairs task order worth as much as $18.3 million took effect on September 30, 2026.
Tempus, founded by Eric Lefkofsky, is one of the largest AI-driven precision medicine companies, combining genomic testing with clinical data and artificial intelligence. Bringing Personalis inside Tempus would consolidate two businesses that already work together commercially, which is the strategic logic of the deal — and also the source of the governance questions around it.
Why It Matters for Founders and Investors
The Personalis deal is a compact lesson in how acquisitions of public companies actually work. The headline price is only the starting point: the form of consideration, the collar, the shareholder vote and the fiduciary-duty scrutiny all determine what shareholders end up with. For founders, the key takeaway is about related-party risk — if your largest investor or your biggest commercial partner is also your most likely acquirer, expect the price to be challenged and the process to be examined. For investors, the November 30 vote is the decision point, and the collar means the value of the deal is still moving with Tempus's share price until closing.
Angeled.com connects founders with investors.
Bullished, "Personalis (PSNL) Tells Holders To Back Tempus Deal Worth $16.25 A Share In Stock, Citing 28% And 64% Premiums," October 30, 2026
Kalkine, "Why Did Personalis (NASDAQ:PSNL) Sales Surge 77% to USD 25.6 Million as Losses Grew?," November 2026
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



